- Home
- HNRG vs DCTH Comparison
HNRG vs DCTH Comparison
Compare HNRG & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HNRG
- DCTH
- Stock Information
- Founded
- HNRG 1949
- DCTH 1988
- Country
- HNRG United States
- DCTH United States
- Employees
- HNRG N/A
- DCTH N/A
- Industry
- HNRG Coal Mining
- DCTH Medical/Dental Instruments
- Sector
- HNRG Energy
- DCTH Health Care
- Exchange
- HNRG Nasdaq
- DCTH Nasdaq
- Market Cap
- HNRG 632.2M
- DCTH 630.4M
- IPO Year
- HNRG N/A
- DCTH N/A
- Fundamental
- Price
- HNRG $15.32
- DCTH $13.85
- Analyst Decision
- HNRG Strong Buy
- DCTH Strong Buy
- Analyst Count
- HNRG 3
- DCTH 4
- Target Price
- HNRG $18.33
- DCTH $24.00
- AVG Volume (30 Days)
- HNRG 746.0K
- DCTH 508.4K
- Earning Date
- HNRG 08-05-2025
- DCTH 08-04-2025
- Dividend Yield
- HNRG N/A
- DCTH N/A
- EPS Growth
- HNRG N/A
- DCTH N/A
- EPS
- HNRG N/A
- DCTH N/A
- Revenue
- HNRG $410,607,000.00
- DCTH $53,850,000.00
- Revenue This Year
- HNRG N/A
- DCTH $155.42
- Revenue Next Year
- HNRG $9.86
- DCTH $37.93
- P/E Ratio
- HNRG N/A
- DCTH N/A
- Revenue Growth
- HNRG N/A
- DCTH 1068.87
- 52 Week Low
- HNRG $4.86
- DCTH $7.17
- 52 Week High
- HNRG $19.71
- DCTH $18.23
- Technical
- Relative Strength Index (RSI)
- HNRG 38.36
- DCTH 37.03
- Support Level
- HNRG $15.92
- DCTH $15.72
- Resistance Level
- HNRG $16.75
- DCTH $17.35
- Average True Range (ATR)
- HNRG 0.78
- DCTH 0.74
- MACD
- HNRG -0.27
- DCTH -0.40
- Stochastic Oscillator
- HNRG 0.91
- DCTH 2.23
About HNRG Hallador Energy Company
Hallador Energy Co is a coal mining company with operations in Indiana, USA, and it is part of the electric power generation industry. The operations of the company are divided into two primary reportable segments, the Coal Operations and Electric Operations segments. The majority of revenue is earned from the Coal Operations segment.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.